Page last updated: 2024-09-03

astragaloside a and Hypertension, Pulmonary

astragaloside a has been researched along with Hypertension, Pulmonary in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's5 (100.00)2.80

Authors

AuthorsStudies
Dai, A; Li, C; Li, G; Li, S; Meng, F; Wu, S; Zha, J; Zhang, S; Zhu, H; Zhu, L1
Feng, Y; Gao, X; Hao, X; Li, L; Long, Y; Zhang, J; Zhang, S; Zhang, X1
Liu, Y; Lu, ML; Tang, BL; Wang, HX1
Li, R; Liu, D; Ma, Y; Xi, J1
Guo, L; Jiao, Y; Jin, H; Kim, SC; Li, X; Liu, J; Ma, Y; Shen, L; Zhao, R; Zhou, Z1

Other Studies

5 other study(ies) available for astragaloside a and Hypertension, Pulmonary

ArticleYear
Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, Jul-20, Volume: 102

    Topics: Animals; Hypertension, Pulmonary; Hypoxia; Mice; Pulmonary Artery; Quality of Life; Saponins; Sildenafil Citrate; T Follicular Helper Cells; Triterpenes; Vascular Remodeling

2022
Astragaloside IV in Hypoxic Pulmonary Hypertension: an In Vivo and In Vitro Experiments.
    Applied biochemistry and biotechnology, 2022, Volume: 194, Issue:12

    Topics: Animals; Disease Models, Animal; Hypertension, Pulmonary; Hypoxia; Monocrotaline; Rats; Saponins; Tumor Necrosis Factor-alpha

2022
Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway.
    Journal of cellular and molecular medicine, 2023, Volume: 27, Issue:5

    Topics: Animals; Disease Models, Animal; Endothelial Cells; Epidermal Growth Factor; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Hypoxia; Male; MAP Kinase Signaling System; Oxygen; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Rats, Sprague-Dawley

2023
Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway.
    BMC pulmonary medicine, 2023, Oct-12, Volume: 23, Issue:1

    Topics: Animals; Cell Proliferation; Fibrosis; Hypertension, Pulmonary; Hypoxia; Myocytes, Smooth Muscle; Prolyl Hydroxylases; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyroptosis; Rats; Signal Transduction

2023
Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling.
    International journal of molecular medicine, 2021, Volume: 47, Issue:2

    Topics: Animals; Hypertension, Pulmonary; Inflammation; Male; Monocrotaline; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Saponins; Triterpenes; Vascular Remodeling

2021